CFDE Data Portal | Search IQCK-AS1

	Label	Description
	IQCK-AS1 Gene (Entity type)	ENSG00000261195 - IQCK antisense RNA 1
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE125157 1 V 0 PICEATANNOL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

IQCK-AS1

ENSG00000261195 - IQCK antisense RNA 1

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 5 human dn

A Gene Set from LINCS

GSE125157 1 V 0 PICEATANNOL MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.